摘要
靶向治疗因其特异性高和毒副作用小等优势,在白血病及淋巴瘤等儿科常见血液系统肿瘤治疗中具有重要作用。单克隆抗体如CD20单克隆抗体(利妥昔单抗)治疗B细胞淋巴瘤,酪氨酸激酶抑制剂(TKI)如BCR/ABL抑制剂(甲磺酸伊马替尼)治疗慢性粒细胞白血病(CML),泛素-蛋白酶体抑制剂治疗复发急性白血病等疗效显著的品种,以及新型靶向治疗如抗体偶联药物等在儿科临床中的应用均为临床关注热点。本文简要综述儿童白血病和淋巴瘤靶向治疗药物的临床评价及其研究进展。
Targeted therapy plays an important role in the treatment of leukemia and lymphoma with its higher specificity and fewer adverse reactions. The remarkable outcomes including CD20 monoclonal antibody (rituximab) in B-cell lymphoma, BCR/ABL inhibitor (imatinib mesylate) in CML and ubiquitin proteasome inhibitor in relapsed acute leukemia have been found. In addition, new targeted therapy such as antibody-drug conjugates also has been found good results in clinics. Targeted therapy has become a hotspot in the treatment of hematological malignancy. This review describes advances in targeted therapy of childhood for leukemia and lymphoma.
出处
《世界临床药物》
CAS
2015年第5期298-304,共7页
World Clinical Drug
基金
上海市人才发展基金(2012051)
关键词
儿童
白血病
淋巴瘤
靶向治疗
childhood
leukemia
lymphoma
targeted therapy